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A deficiency of protein C (PC), antithrombin, or protein S is
strongly associated with deep-vein thrombosis in selected
patients and their families. However, the strength of the
association with venous thrombosis in the general popula-
tion is unknown. This study was a population-based, pa-
tient-control study of 474 consecutive outpatients, aged less
than 70 years, with a first, objectively diagnosed, episode of
venous thrombosis and without an underlying malignant
disease, and 474 healthy controls who matched for age and
sex. Relative risks were estimated äs matched odds ratios.
Based on a single measurement, there were 22 (4.6%) pa-
tients with a PC deficiency (PC activity, less than 0.67 U/mL
or PC antigen, less than 0.33 U/mL when using coumarins).
Among the controls, the frequency was 1.5% (seven sub-
jects). Thus, there φ& threefold increase in risk of thrombo-
sis in subjects with PC levels below 0.67 or 0.33 U/mL
PROTEIN C, PROTEIN S, and antithrombin are compo-nents of physiologically important anticoagulant Sys-
tems.1"3 A deficiency of these proteins can cause thrombosis
due to shortage of coagulation Inhibition.
To date, a number of investigators have provided estimates
of the prevalence of deficiencies of these three major coagu-
lation Inhibitors in selected patient groups or in large popula-
tions of healthy individuals.4"'0 Obviously, the wide ränge in
these observed prevalences is related to the selection of the
subjects.
Heterozygosity for protein C deficiency, and also for pro-
tein S and antithrombin deficiency, has been associated with
a tendency to venous thrombosis in selected patients and
their families."·12 The total frequencies of these defects
among thrombosis patients have been estimated at 3% to
8%.4·5 This view was challenged by Miletich et al8 in 1987,
who, among 5,422 healthy blood donors, identified 79 sub-
jects with low protein C levels, none of whom had a personal
or family history of venous thrombotic disease.
The results of the studies in selected groups, are probably
overstated: in studies that investigated a selected group of
patients with repeated thrombosis at a younger age or with
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[matched odds ratio, 3.1; 95% confidence interval (CD, 1.4
to 7.0]. When a PC deficiency was based on two repeated
measurements, the relative risk for thrombosis increased to
3.8 (95% Cl, 1.3 to 10); when it was based on DNA-confirma-
tion, the relative risk increased further to 6.5 (95% Cl, 1.8 to
24). In addition, there was a gradient in thrombosis risk,
according to PC levels. The results for antithrombin are simi-
lar to those for PC, although less pronounced (relative risk,
2.2; 95% Cl, 1.0 to 4.7). We could not find an association
between reduced total protein S (relative risk, 0.7; 95% Cl,
0.3 to 1.8) or free protein S levels (relative risk, 1.6; 95% Cl,
0.6 to 4.0) and thrombosis risk. Although not very frequent,
PC and antithrombin deficiency are clearly associated with
an increase in thrombosis risk.
© 7935 by The American Society of Hematology.
a clear familial risk, the association between a protein defi-
ciency and deep-vein thrombosis is likely to be higher than
in the average thrombosis patient. In contrast, among healthy
blood donors recruited on the basis of absence of previous
disease, the relation between a protein deficiency and throm-
bosis is likely to be underestimated. More importantly, most
studies were uncontrolled; ie, there was no reference group
or index group, which is crucial to investigate the association
between a deficiency and venous thrombosis. The study by
Heijboer et al7 was the first controlled study that included
277 patients and 138 control subjects. However, this study
was not designed to estimate the association between the
hereditary deficiency and venous thrombosis, but rather to
assess the positive predictive value for the presence of an
isolated protein deficiency in patients with recurrent, famil-
ial, or juvenile deep-vein thrombosis. In another controlled
pedigree study by Allaart et al," it was reported that truly
heterozygous protein C-deficient individuals had a ninefold
higher thrombosis risk than their nondeficient family mem-
bers. Nondeficient family members are excellent controls to
investigate the etiologic question of the association between
a deficiency and thrombosis, äs they closely resemble the
index group.· They are less appropriate, however, to estimate
the size of the relative risk when these families are identified
by a highly selective referral process. This may lead to an
underestimate of the true risk, eg, when the presence of
other, possibly yet unidentified, risk factors in the family
contributed to their thrombophilia, or it may lead to an over-
estimate, when families with an abundance of thrombosis (ie,
with several probands) are selectively diagnosed or referred.
At present, the impact of a deficiency of one of the major
coagulation Inhibitors äs a cause of venous thrombosis in
the general population is still unclear. Therefore, we have
investigated 474 unselected and consecutive patients, aged
less than 70 years, with a first, objectively confirmed episode
of deep-vein thrombosis and without underlying malignant
disease and compared the plasma levels of protein C. protein
S, and antithrombin with those of 474 matched healthy con-
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trol subjects. The study was pari of a population-based, case-
control study on hereditary venous thrombosis: the Leiden
Thrombophilia Study (LETS).
PATIENTS AND METHODS
Study design. Patients were selected from the files of the Antico-
agulation Clinics in Leiden, Amsterdam, and Rotterdam, The Nether-
lands. In The Netherlands, anticoagulation clinics monitor coumarin
treatment in virtually all patients with venous thrombosis, with each
clinic monitoring for patients in a well-defined geographic area.1415
As all of our patients originated from one of these areas, geography
was the first criterion for eligibility. We included all 474 consecutive
outpatients aged younger than 70 years who were referred for diag-
nosis or monitoring of anticoagulant treatment after a first, objec-
tively confirmed episode of deep vein thrombosis that occurred be-
tween January l, 1988, and December 31, 1992 (Leiden area, n =
271); January l, 1989, and December 31, 1992 (Amsterdam area, n
= 90); and January l, 1990, and June 31, 1992 (Rotterdam area, n
= 113). Patients with known malignant disorders were excluded.
Information about the inclusion and exclusion criteria was obtained
from general practitioners, from discharge records from the hospitals,
and from the records of the anticoagulation clinics. Patients on short-
term coumarin treatment were seen only after anticoagulant treat-
ment was discontinued for at ||>st 3 months. Forty-eight (10%) of
the 474 included patients, however, were on long-term coumarin
treatment and were not allowed to Interrupt their medication for
various reasons: of these 48 patients, 16 patients had recurrent throm-
bosis before the end of the study, 11 patients had additional cardiac
indications (myocardial infarction, atrial fibrillation, coronary bypass
grafting, congenital abnormalities), seven patients were already
known to have a coagulation inhibitor deficiency, six patients had
peripheral arterial disease, two patients had severe postthrombotic
Symptoms, and six patients had other, mainly prophylactic, indica-
tions. The median time between the occurrence of the deep-vein
thrombosis and venepuncture for this study was 19 (ränge, 6 to 68)
months. Of eligible patients, 90% were willing to participate in the
study.
Each thrombosis patient was asked to find his own healthy control
subject according to the following criteria: same sex, same age (±5
years), no biologic relationship, no history of venous thromboembo-
lism, no use of coumarins for at least 3 months, and no known
malignant disorders. Partners of patients were also invited to volun-
teer äs control subjects. When a patient was unable to find a control
subject, the first individual from the list of partners who matched
for age and sex was asked to join the study; 225 (47%) matched
control subjects were partners of other patients. The control subjects
and cases were inhabitants of the same geographic areas.
All subjects completed a Standard questionnaire that contained
questions about hormone use at the time of the venepuncture and
about the presence of acquired risk factors in the past, confined to
a specific period before the index date (ie, date of the thrombotic
event). As acquired risk factors, we considered surgery or hospital-
izations in the year preceding the index date, postpartum periods
(within 30 days of the index date); and pregnancy at the time of the
index date.
Laboratory studies. Blood was collected from the antecubital
vein into Monovette tubes (Sarstedt, Niimbrecht, Germany) con-
taining 0.106 mmoI/L trisodium citrate. Plasma was prepared by
centrifugation for 10 minutes at 2,000g at room temperature and
stored at -70°C in 1.5 mL'volumes until used. High-molecular-
weight DNA was isolated from leukocytes and stored at 4°C.
Protein C activity and antithrombin activity were measured with
Coamate (Chromogenix, Mölndal, Sweden); factor II activity, with
a chromogenic method using S-2238 (Chromogenix) and Echis Cari-
natus16 (Sigma Chemical Co, St Louis. MO) on an ACL 200 (Instru-
mentation Laboratory, Milan, Italy). Protein C antigen was assessed
by electroimmunoassay äs described elsewhere.'7 Total protein S
was measured by polyclonal enzyme-linked immunosorbent assay
(ELISA),'8 and free protein S was measured directly in plasma by
ELISA using two monoclonal antibodies specific for free protein S
(Asserachrom free Protein S, Stago Diagnostica, Asnieres-sur-Seine,
France)."·20 The results are expressed in units per milliliter, where
l U refers to the activity or antigen present in l mL pooled normal
plasma (so, l U/mL = 100%). The activated partial thromboplastin
time (APTT), prothrombin time; and thrombin time were measured
using Cephotest (Nycomed, Oslo, Norway), Thromborel S (Beh-
ringwerke AG, Marburg, Germany), and Thrombin Reagent (Baxter,
Miami, FL), respectively, on an Electra 1000 (MLA, Pleasantville,
NY).
For the identification of mutations in the protein C gene, we used
polymerase chain reaction (PCR) amplification followed by direct
sequencing.21
To exclude observer bias, the technicians were blinded to the
Status of the sample, ie, whether it was from a patient or a control
subject.
The criteria for the diagnosis of protein deficiencies were plasma
levels below the lower limit of normal, äs used in our laboratory,
combined with normal values of factor II and prothrombin tirne (to
exclude a vitamin K deficiency or coumarin use). The lower limits
of normal were 0.67 U/mL for protein C and total grotein S and
0.80 U/mL for antithrombin. For the new free protein S assay, a
reference ränge was derived from the results in the healthy control
subjects. After logarithmic transformation of the data, the lower limit
of normal was 0.57 U/mL (mean minus l .96 SD; none of the subjects
had values outside 3 SD of the mean). For those on stable long-
term coumarin therapy, the lower limit of normal for protein C
antigen (Laurell) and total protein S antiken was 0.33 U/mL. For
the primary analysis, we only used the outcomes of the first measure-
ments. In all subjects with a protein C level below 0.67 (or 0.33)
U/mL, DNA analysis was performed. For secondary analysis, all
subjects with protein C, total protein S, or antithrombin levels below
the cut-off points were seen on a second occasion for re-evaluation.
Analysis and statistics. We calculated relative risks, äs estimates
of the crude matched odds ratios, for each of the protein deficiencies
by simple crosstabulation. We used Miettinen's test-based 95% con-
fidence limits.22 The relative risk reflects the thrombosis risk when
the plasma level is below a certain limit relative to the risk when it
is within the normal ränge, adjusted for the matching factors of age
and sex. As the plasma levels of the inhibitory proteins have a
continuum of values instead of binary outcomes, we examined if
there was a relation between the plasma levels and thrombosis risk
(dose-response) by calculating relative risks over levels of the plasma
factor (only for those not on oral anticoagulants).
RESULTS
The mean age for patients and controls was 47 years
(ränge, 16 to 70 years for patients, 16 to 73 years for con-
trols); and the malerfemale ratio among patients and controls
alike was 3:4.
Table l lists the risk estimates for protein C. Based on a
single measurement, the relative risk for thrombosis was 3.1
(95% confidence interval [CI], 1.4 to 7.0). In a secondary
analysis, which included the re-evaluation in 28 subjects
with initially low levels (one patient was not available), the
thrombosis risk for persistently low results became almost
4. For all subjects with initial plasma levels below 0.67 U/
mL, the protein C gene was investigated. In 13 patients and
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Table 1. Comparison of Prevalence and Thrombosis Risk
in 474 Patients and 474 Control Subjects for Several Definitions of
a Protein C Deficiency
Definition of Protein C Deficiency No. of No. of
(lower limit of normal Patients Controls
for those on coumarin) (%) {%) OR* 95% Cl
First measurement
<0.67 U/mL (0.33) 22(4.6) 7(1.5) 3.1 1.7-7.0
First and second measurement
<0.67 U/mL (0.33) 15 (3.1) 4 (0.8) 3.8 1.3-10
First measurement
<0.67 U/mL (0.33) and the
presence of a mutation 13(2.7) 2(0.4) 6.5 1.8-24
Abbreviation: OR, age- and sex-matched odds ratio.
* All discordant patient-control pairs.
Table 3. Thrombosis Risk for Categories
of Protein C Activity Levels
Protein C Strata
(U/mL)
<0.55
0.55-0.65
0.65-0.75
0.75-0.85
==0.85
No. of Patients
4(4)
10(5)
16 (ND)
54 (ND)
342 (ND)
No. of Controls
1 (D
3(2)
10 (ND)
44 (ND)
368 (ND)
OR*
4.0
3.7
1.8
1.3
1.0t
95% Cl
0.5-36
1.0-13
0.8-4.2
0.9-2.0
Patient-control pairs (n = 426) without coumarin use (first measure-
ments). Data in parentheses indicate number of subjects in whom a
mutation was found.
Abbreviation: ND, not done.
* Test for trend, P< .01.
t Reference category.
two controls, a mutation was found (Table 2), which led to
a thrombosis riskifor abnormally low levels of protein C
confirmed by DN/ülhalysis of 6.5 (95% Cl, 1.8 to 24). Table
l also shows the drop in prevalence of a protein C deficiency
among patients (from 4.6% to 2.7%) and controls (from
1.5% to 0.4%) when more stringent criteria were used to
establish a diagnosis. This resulted in a clear increase of the
relative risk for thrombosis (from 3.1 to 6.5).
Table 3 gives the odds ratios for the categories of protein
C plasma levels, especially in the ränge where discrimination
between true heterozygotes and normal individuals with low
levels is difficult. It shows an inverse relation between the
risk of thrombosis and the plasma level of protein C, for
levels below the reference category (5=0.85 U/mL).
Table4 shows that we found slightly more control subjects
than patients with initial and persistently low total protein S
levels, which ranged from 0.45 to 0.66 U/mL among the
controls, and from 0.59 to 0.65 U/mL among the patients
(0.26 to 0.27 U/mL for two patients on oral anticoagulant
treatment). Thus, there was no association between low total
protein S levels and thrombosis risk. The male:female ratio
within individuals with low protein S levels was 2:17 (among
those low at remeasurement, 2:9), and contrasted with the
male:female ratio for protein C-deficient (13:16) and anti-
thrombin-deficient (13:11) subjects. The two males with low
total protein S levels were both from the patient group. There
Table 2. Protein C Mutations in 13 Patients
and Two Control Subjects
Exon
6
7
9
9
9
9
Nucleotide
Position and
Mutation
1515, G-Ά
_
3439, C -* T
6219, G-» A
8403, C -» T
8505, Ins TGG
8506, Ins TGGC
8631, C-* T
Amino Acid Change
Nons, near 5 donor
splice junction of
intron C
132, Q -» stop
169, R-> Q
230, R - C
264, ins V; in frame
insertion
Frameshift, stop at 331
306, R -· stop
No. of No. of
Patients Controls
1
1
2
7 1
1
1
1
was no difference in frequency of oral contraceptive use
between female patients (67%) and controls (73%) with low
protein S levels.
Based on a single free protein S measurement in the 426
patient-control pairs not using oral anticoagulants, the rela-
tive risk for thrombosis was 1.6 (95% Cl, 0.6 to 4.0). When
we used both total and free protein S levels below the lower
limit of normal äs criteria for the diagnosis of a protein S
deficiency, the relative risk became 1.7 (95% Cl, 0.4 to 6.9).
Table 4 also gives the risk estimates for antithrombin.
Based on one measurement, the relative risk for thrombosis
Table 4. Comparison of Prevalence and Thrombosis Risk
in Thrombosis Patients and Control Subjects for Protein S
and Antithrombin Deficiency
No. of
Patients
No. of
Controls
Criterion of a Deficiency OR 95% Cl
Total protein S (lower limit of
normal for those on
coumarin)
First measurement
<0.67 U/mL (0.33) 8(1.7) 11(2.3) 0.7* 0.3-1.8
First and second measurement
<0.67 U/mL (0.33)
Free protein Si
First measurement
<0.57 U/mL
Total and free protein St
Both below lower limits of
normal
Antithrombin
First measurement
<0.80 U/mL
First and second measurement
<0.80 U/mL
5(1.1) 6(1.3) 0.8t 0.2-3.0
13(3.1) 9(2.1) 1.6i 0.6-4.0
5(1.2) 3(0.7) 1.7§ 0.4-6.9
20(4.2) 9(1.9) 2.2§ 1.0-4.7
5(1.1) 1 (0.2) 5.0§ 0.7-34
* Seventeen discordant patient-control pairs; in seven of the pairs,
the patient had a Iowered protein S level and the control subject did
not.
t Nine discordant patient-control pairs; in four of the pairs, the pa-
tient had a Iowered protein S level and the control subject did not.
Φ Patient-control pairs (n = 426) not using oral anticoagulants.
§ All discordant patient-control pairs.
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Table 5. Frequency of Acquired Risk Factors in Patients With and
Without a Coagulation Inhibitor Deficiency and in Healthy Controls
Presence of Acquired
Risk Factor* (%)
Yes
Thrombosis patients
With abnormal PC/PS/AT testet
With normal PC/PS/AT testst
Control subjects
31
34
6
69
66
94
Abbreviations: PC, protein C; PS, protein S; AT, antithrombin.
* Considered were surgery, hospitalization, pregnancy, postpartum
bedrest, and prolonged immobilization.
t The proportions did not alter when only PC and AT were consid-
ered.
was 2.2 (95% Cl, 1.0 to 4.7) and became 5.0 (95% Cl, 0.7
to 34) when it was based on two persistently low measure-
ments. There was insufficient Variation in plasma levels to
perform a dose-response analysis (27 of the 29 subjects with
initially lowered levels had values between 0.70 and 0.80
U/mL). fk
The number of subjects in whom at least one acquired
risk factor was present in the period before the thrombotic
event (or before the index date for the control subjects) is
presented in Table 5. It shows that acquired risk factors were
equally frequent among thrombosis patients with normal and
with abnormal test outcomes for one of the coagulation in-
hibitors (difference, 3%; 95% Cl, -17% to 12%), showing
that spontaneous thrombotic episodes are not at all limited
to the group with protein deficiencies. Among the healthy
controls, acquired risk factors were also frequently present
(6%), demonstrating that these acquired states in themselves
are insufficient to cause thrombosis.
DISCUSSION
Among 474 consecutive patients aged less than 70 years
with a first, objectively diagnosed episode of venous throm-
bosis and without an underlying malignancy, functional pro-
tein C deficiency was the most frequent coagulation inhibitor
deficiency. Protein C deficiency also conferred the highest
relative risk of thrombosis. Additionally, there was a gradient
of thrombosis risk according to protein C levels. When strin-
gent diagnostic criteria were applied, the relative risk became
6.5, which is likely due to less misclassification and, there-
fore, is the most reliable estimate of the relative risk of
thrombosis associated with hereditary protein C deficiency.
The results for antithrombin are approximately similar to
those for protein C, although somewhat less pronounced.
Low protein S levels were not associated with an increased
thrombosis risk.
Depending on the applied criteria, the prevalence of pro-
tein C deficiency among the controls varied from 1.5% to
0.4%. These figures (l:70-to 1:250) are strikingly similar to
those reported by Miletich et al,8 who found 79 (1.5%) of
5,422 healthy blood donors with antigen levels below 65%
of normal. Of these 79 subjects, 62 to 71 were considered
likely to be pari of the continuous distribution of normal,
which led to an extrapolated estimated prevalence of l in
200 to l in 300. This shows that the study by Miletich
et al8 gave reproducible prevalence figures for a healthy
population but did not clarify the risk of thrombosis.
The prevalence of a protein C deficiency among our unse-
lected outpatients was 2.7% to 4.6%, again depending on
the criteria, which is similar to the 3.2% (95% Cl, l .5% to
6.2%) prevalence reported by Heijboer et al7 but is lower
than reported in studies that investigated patients with a
history of unusual thrombosis at an early age.45 Obviously,
this relates largely to the method of patient selection in the
different groups.
Seven distinct mutations were shared by the 15 subjects
in whom a protein C gene abnormality was identified (Table
2). The position-230, R -» C replacement was most common
and was present in seven patients and one control. The posi-
tion-169, R -» Q Substitution recurred twice, whereas the
remaining five mutations all occurred once. Three of the
mutations resulted in premature stop codons. This leaves no
room for doubt regarding the causative relationship between
low protein C levels and mutation. The relationship between
half-normal functional levels of protein C is also obvious
for the position-169, R -» Q replacement, which involves
the arginine in the cleavage site for thrombin. The position-
230, R -> C Substitution is believed to be the direct cause of
the protein C deficiency, äs this defect is the most common
abnormality in Dutch protein C-deficient subjects.2' The mu-
tation that leads to the insertion of a valine after amino acid
position 264 is novel, and, presently, there are no additional
data that support the causative nature of this mutation. Com-
parison of the homologous amino acid sequences of protein
C, factor IX, factor VII, factor X, and prothrombin shows
that the mutation is in a Stretch of two nonconserved amino
acids that are flanked by two invariable amino acids at posi-
tions 263 and 266. From this it seems reasonable to hypothe-
size that the mutation disrupts the correct folding of the
protein C molecule. More problematic is the Interpretation
of the position-1515, G -> A transition. This nucleotide re-
placement occurs 15 nucleotides into intron C. It does not
seem to create a new consensus sequence for splicing. There-
fore, it is possible that the mutation represents a rare se-
quence variant without functional consequences. One should
also note that we do not know whether the nucleotide change
is in the allele that putatively cosegregates with the protein
C deficiency. This doubt about the certainty of a protein C
deficiency in one of the two control subjects may lead to a
twofold error in our estimate of the relative risk (6.5 v 13);
ie, the true risk might be twice äs high äs reported in Table
1.
To date, studies among healthy blood donors and among
highly selected patient groups have provided estimates of
the prevalence within particular populations. However, such
prevalences are insufficient to quantify the relation between
a deficiency and thrombosis risk. To answer this question,
a comparison between unselected patients and population-
based thrombosis-free controls is necessary. The controls in
the study of Heijboer et al7 were individuals suspected of
deep-vein thrombosis that could not be confirmed by imped-
ance plethysmography. These individuals do not constitute
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a satisfactory sample of the population of thrombosis-free
controls, äs impedance plethysmography is insensitive in
detecting calf-vein thrombosis.23 It is, therefore, likely that
some of these individuals actually had venous thrombosis
of the calf veins, which might have been caused by a protein
C deficiency. The result of a 1.4% prevalence of a protein
C deficiency among the controls, defined äs at least two
measurements below the lower limit of normal, might, there-
fore, have been an overestimate. This is supported by the
present results; we found a twofold lower prevalence (0.8%)
with persistent lowered protein C levels among the controls
(two measurements on fresh blood samples).
To our surprise, we found that lowered total protein S
levels were not associated with venous thrombosis. By using
lower cut-off points, we consistently found slightly more
control subjects than patients with lower values (data not
shown). Even among those who repeatedly had low levels,
controls were overrepresented. The male:female (2:17) ratio
was also unexpectgd for an autosomal inherited disorder.
Therefore, we invesligated, by multiple linear regression
analysis, the influence of oral contraceptives on the protein
S level; among the female controls, the age-adjusted reduc-
tion in protein S levels was on average 0.09 U/mL for pill
users. However, this difference in protein S levels does not
explain our result, äs the number of women with low protein
S levels who were using oral contraceptives was approxi-
mately similar for patients and controls. It does show that
different cut-off points for protein S antigen levels are re-
quired for males and females, if not also for pill users and
non-pill users. Nevertheless, even with a separate analysis
for men and women and the strictest cut-off point for nonan-
ticoagulated subjects, no clear thrombosis risk emerged (fe-
males, 0 cases and two controls <0.55 U/mL; no males with
levels sO.55 U/mL). Our result is in disagreement with
many reports of protein S-deficient kindreds, in which ve-
nous thrombosis appears highly prevalent and is clearly re-
lated to the deficiency.24"26 One possibility might be that
protein S deficiency is so rare that we found only a few
hereditary deficiencies. This explanation seems unsatisfac-
tory, äs we found two control subjects who had persistent
levels at 0.50 U/mL: ie, were very likely heterozygous. This
renders an extremely low prevalence of the deficiency in the
general population unlikely. We, therefore, believe that the
possibility that the previous findings in families are the result
of cosegregating additional genetic defects should be seri-
ously considered. The possibility that protein S is not a clear
risk factor for deep-vein thrombosis in unselected consecu-
tive patients is further supported by the finding that, in Sys-
tems of purified proteins, protein S has littie cofactor activity
to activated protein C.27'"8 The data on the free protein S
assay showed also no clear relation between a deficiency and
thrombosis, although a positive effect cannot be excluded.
The prevalences of low levels of antithrombin are in
agreement with the recent literature. Heijboer et al7 reported
a strikingly similar prevalence for repeatedly low levels of
antithrombin of l. l % among unselected patients with throm-
bosis. A relative risk could not be recalculated from that
report, äs all 138 control subjects had normal antithrombin
levels. In the present study, the relative risk varied from 2.2
to 5.0, depending on the applied criteria. The prevalence of
antithrombin deficiency among the controls was 1.9% (one
measurement) or 0.2% (two repeated measurements), which
is close to the recently reported prevalences in healthy blood
donors.9'29 These findings indicate that antithrombin defi-
ciency is a very rare disease, and this probably explains why
our relative risk estimate of 5.0 could not reach statistical
significance.
The control subjects were selected by the patients. We do
not believe that this practice may have biased our findings
on these hereditary abnormalities in the coagulation System,
äs it is difficult to imagine that patients choose their friends
or partners on the basis of unknown plasma levels of antico-
agulant proteins.
This population-based, case-control study confirms that,
among unselected patients, the prevalence of a (hereditary)
protein C deficiency and of lowered protein S and antithrom-
bin plasma levels is relatively low compared with the 20%
prevalence of activated protein C-resistance (factor V
Leiden) among unselected patients.303' Although the clinical
bürden is, therefore, limited, protein C deficiency clearly
confers a threefold to almost sevenfold increase in risk of
thrombosis.
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